Navigation Links
Excalibur - 'Transforming' Biotech Deals can Still be Achieved
Date:10/1/2008

LONDON, October 1 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today 'transforming' deals could still be achieved in the UK biotech sector despite the most severe market conditions.

Excalibur, founded by Professor Sir Christopher Evans and a development of Merlin Biosciences, was instrumental in securing important funding to enable York Pharma plc, the specialist dermatology company, to make a significant product acquisition which will propel the company into profit and generate significant revenues.

Following York Pharma's announcement today (Wednesday) that it has completed the EUR28.5 million financing package to fund the acquisition, Professor Sir Christopher Evans, chairman of Excalibur, said: "This is exactly what everyone wants to see in the UK biotech sector, where a loss-making company can be turned into a revenue generating and profitable operation offering products to the market.

"Excalibur was delighted to assist York Pharma through an investment by Merlin Biosciences Fund III while the company secured additional funding from the United States. While it is extremely reassuring that investment funding is still available from the USA, it is important in the UK biotech sector to show that such transforming deals can be achieved despite the grim economic picture."

York Pharma has acquired the sales and worldwide commercial rights to two dermatological/wound care products, Flammazine and Flammacerium, from Solvay Pharmaceuticals. The products are sold in 21 countries and are used in the prevention and treatment of infections in burn wounds and tropical wounds. The products generate annual revenues of GBP8.5 million.

Sir Christopher commented: "Last year York Pharma acquired a Merlin Biosciences Fund III company, Derms Developments, which gave it a sales, marketing and product offering. This deal now means the company can take another important step forward and we're sure that York will go from strength to strength and we are pleased to see it send out a strong signal to the biotech industry."

Notes to Editors

About Excalibur

Excalibur was launched in April this year and operates across the entire medical sciences sector. It has adopted the successful investment strategy of Merlin's Fund III which has focused more broadly on healthcare and medical science investments and is already delivering significant returns to investors with four more years to run.

Further information: Ramsay Smith, Media House International. Tel: +44(0)207-397-8460/+44(0)7788-414856. Email: ramsay@mediahouse.co.uk


'/>"/>
SOURCE Excalibur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
2. SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID
3. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
4. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
5. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
8. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
9. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
10. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
11. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):